Ikove Startup Nursery

Ikove operates a 12-month internal R&D phase before company formation — its employed engineers and product managers validate the market, build the MVP, and conduct customer discovery. The firm only hires a founding CEO once product-market fit signals are clear. This moves technical risk inside the firm, whereas most accelerators accept external founding teams at application and compress validation into weeks.

Managing Partners Flavio Lobato and Johnny Hwin make investment committee decisions alongside Co-Founder Marcio R. Campos. Lobato, based in Columbus, leads fund strategy and LP relations, while Hwin and Campos guide the São Paulo R&D operation and deal origination pipeline. All three were previously affiliated with CESAR, the Brazilian innovation institute where the nursery methodology was piloted.

Ikove exclusively creates and seeds its own ventures; it does not invest as a limited partner in external funds. Its capital goes directly into companies birthed from the nursery program, typically through pre-seed and seed instruments. The firm occasionally co-invests alongside later-stage institutional investors — for example, Solinftec attracted growth capital from TPG after graduating from Ikove's portfolio.

Ikove maintains a major R&D studio in São Paulo with roots at CESAR, the Recife-based innovation lab where the founders previously worked. The Brazilian operation provides subsidized engineering talent, customer discovery infrastructure, and a beachhead for deep-tech ideas that require cost-efficient technical validation before transferring to the U.S. market. This cross-border pipeline is Ikove's primary talent moat.

The firm stays away from consumer social media, pure-play e-commerce, and hardware with long prototyping cycles outside its AgriTech focus. Ikove's public portfolio broadly excludes biotech therapeutics requiring FDA approval, crypto tokens, and enterprise businesses that depend on government procurement as the primary revenue source. Investment scope is explicitly limited to deep-tech verticals where the internal R&D bench can add value.

Ikove typically recruits an external CEO after the nursery phase validates demand and builds the initial product. The firm looks for operators who have taken a company from seed to Series B, often within the same vertical. Founders are matched through the partners' networks and granted significant equity, structured as a co-founding relationship with the firm retaining substantial ownership — a departure from the standard startup studio model where the studio owns the majority of equity.

Ikove's disclosed LP relationships include the Ohio Innovation Fund, Rev1 Ventures, and Ohio Third Frontier — state-backed economic-development vehicles that align with the firm's mission to build technology companies in the Midwest. The firm has not disclosed a total AUM number, but public records of these commitments, combined with the self-described ~5-company annual output at $400,000–$1.5 million initial check size, point to a sub-$100 million fund base.